2026-10-20 21:40:01 UTC#489504newconfirmednews
CRSP stock news
CRSP stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire15 wire items
2026-10-19 21:56:43 UTC#483386duplicateconfirmednews
CRISPR Therapeutics appoints A.J. Silver as CFO, succeeding Raju Prasad
2026-10-19 20:34:11 UTC#482990newconfirmednews
AGNC, WAL, and CRSP identified as stocks to watch in after-hours trading
seeking alphaimportance 0.30trust 0.60AGNC Investment Corp. 0Western Alliance Bancorporation 0CRISPR Therapeutics AG 0
2026-10-19 20:30:35 UTC#482952newconfirmednews
CRISPR Therapeutics CFO resigns from position
2026-10-15 21:56:00 UTC#468679newconfirmednews
UBS initiates CRISPR Therapeutics (CRSP) at Neutral
2026-09-21 23:00:01 UTC#345636newconfirmednews
CRISPR Therapeutics Director Ali Behbahani reports $780,935 sale of common shares
tradingviewimportance 0.30trust 0.90CRISPR Therapeutics AG -0.20Ali Behbahani -0.20Behbahani Trust 0
2026-09-21 11:28:15 UTC#342146newconfirmednews
Morningstar declares $0.50 quarterly dividend, completes integration and rebranding of CRSP indexes
tradingviewimportance 0.30trust 0.70Morningstar, Inc. +0.30Center for Research in Security Prices +0.20
2026-09-14 18:14:09 UTC#309299newconfirmednews
CRISPR Therapeutics (CRSP) highlights CASGEVY growth and upcoming year-end data for CTX310, CTX611, and zugo-cel
2026-09-01 19:27:00 UTC#251664updateconfirmedanalysis
Amgen, Arrowhead, and CRISPR shares decline despite positive heart drug trial results at ESC congress
dow_jonesimportance 0.40trust 0.80Amgen Inc. -0.20Arrowhead Pharmaceuticals, Inc. -0.20CRISPR Therapeutics AG -0.20+2 entities
2026-08-31 12:44:00 UTC#242544newconfirmednews
Citizens maintains $80.00 price target on CRISPR Therapeutics (CRSP)
2026-08-04 15:34:00 UTC#124254newconfirmednews
Citigroup maintains Buy rating on CRISPR Therapeutics, raises price target to $88 from $82
2026-08-04 09:20:03 UTC#121683newconfirmednews
CRISPR Therapeutics AG average analyst price target raised to $84.39, 70% upside implied
2026-08-03 21:38:37 UTC#119401updateconfirmednews
CRISPR Therapeutics Q2 adjusted loss of $0.94/share beats $1.20 estimate; revenue $10.18M beats $6.79M
2026-08-03 20:26:45 UTC#119040newconfirmednews
CRISPR Therapeutics Q2 CASGEVY revenue up 151% to $76M; net loss narrows on FDA label expansion
reutersimportance 0.70trust 0.90CRISPR Therapeutics AG +0.60Vertex Pharmaceuticals Incorporated +0.40CASGEVY +0.60+2 entities
2026-07-06 12:52:00 UTC#2673newconfirmednews